Growth Hormone Receptor Antagonists
The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
Pegvisomant is the only member of a new class of drugs that was especially designed to block the GH receptor (GHR) and, therefore, GH action. In this review we will describe the structure and function of GH and its receptor with specific relevance to the discovery and development of GHR antagonists. With respect to clinical applications, we will first discuss the role of pegvisomant in the treatment of acromegaly. Thereafter, the potential role that pegvisomant might play in the treatment and prevention of late complications of diabetes mellitus and cancer will be discussed and compared with those of somatostatin analogs in these settings. GH is secreted by the somatotrophs of the anterior pituitary gland and acts on various tissues to promote growth and influence metabolism (1, 2). GH signal transduction begins with GH binding to a GHR on the plasma membrane (3). The cocrystal structure of the GH-GHR complex indicates that GH interacts with a preformed GHR dimer. This interaction is critical for GH-induced intracellular signal transduction (4). GH has two distinct domains (sites 1 and 2) that bind to the two identical GHRs at the cell surface. After initial, high affinity binding at site I, subsequent binding at site 2 produces functional receptor dimerization (Fig. 1A). After the GH/GHR interaction, a series of intracellular signaling systems are mobilized, ultimately resulting in the activation or inactivation of genes that are responsible for GH phenotypic effects (5). In humans and most mammals, the extracellular part of the GHR can be released from the cell surface by proteolytic cleavage, resulting in the generation of a serum GH-binding protein (6).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Veldhuis, J. D., Bidlingmaier, M., Anderson, S. M., Evans, W. S., Wu, Z., & Strasburger, C. J. (2002) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2001-011885 · Cited by 61
Cited by
Acromegaly: An Endocrine Society Clinical Practice Guideline
Katznelson, L., Laws, E. R., Melmed, S., Molitch, M. E., Murad, M. H., Utz, A., & Wass, J. A. H. (2014) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2014-2700 · Cited by 1,786
Diagnosis and Treatment of Pituitary Adenomas: A Review
Molitch, M. E. (2017) · JAMA · doi:10.1001/jama.2016.19699 · Cited by 933
Interventions to slow aging in humans: are we ready?
Longo, V. D., Antebi, A., Bartke, A., Barzilai, N., Brown‐Borg, H. M., Caruso, C., Curiel, T. J., Cabo, R., Franceschi, C., Gems, D., et al. (2015) · Aging Cell · doi:10.1111/acel.12338 · Cited by 592
“Notably, a dose-dependent decrease of IGF-1 levels is seen in up to 90% of pegvisomant-treated patients (Trainer et al. , 2000; van der Lely et al. , 2001; Kopchick et al. , 2002; van der Lely & Kopchick, 2006).”
Self-citationDelivery of Therapeutic Proteins
Pisal, D. S., Kosloski, M. P., & Balu-Iyer, S. V. (2010) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.22054 · Cited by 532
The Pharmacology of PEGylation: Balancing PD with PK to Generate Novel Therapeutics
Fishburn, C. S. (2008) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.21278 · Cited by 474
Metadata
- Authors
- Muller, A. F., Kopchick, J. J., Flyvbjerg, A., & van der Lely, A. J.
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2004-04
- Volume
- 89
- Issue
- 4
- Pages
- 1503-1511
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W2066190724
- Cited by
- 90
- References
- 1
- FWCI
- 5.34
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.